For the Quarter Ending September 2025
North America
• In the United States, the Enoxaparin Sodium Price Index rose quarter-over-quarter in Q3 2025, driven by escalating production costs.
• Enoxaparin Sodium production costs increased during Q3 2025, influenced by a 2.6% PPI rise in August 2025.
• Demand for Enoxaparin Sodium expanded in Q3 2025, supported by global pharmaceutical market growth.
• The Enoxaparin Sodium Price Index reflected higher operational expenses due to a 3.0% CPI increase in September 2025.
• Porcine intestinal mucosa costs were elevated in Q3 2025, impacting Enoxaparin Sodium production expenses.
• Natural gas prices surged in September 2025, contributing to increased energy feedstock costs for manufacturing.
• Limited pork inventories persisted in Q3 2025, creating supply challenges for Enoxaparin Sodium raw materials.
• A low unemployment rate of 4.3% in September 2025 supported broader healthcare access and demand for essential drugs.
• Retail sales increased by 5.42% YoY in September 2025, indirectly supporting the healthcare ecosystem and patient affordability.
Why did the price of Enoxaparin Sodium change in September 2025 in North America?
• Porcine intestinal mucosa costs were elevated in Q3 2025 due to limited inventories and robust demand.
• Natural gas prices surged in September 2025, increasing operational expenses for manufacturers.
• A 2.6% PPI rise in August 2025 signaled higher input costs for Enoxaparin Sodium production.
APAC
• In China, the Enoxaparin Sodium Price Index faced downward pressure in Q3 2025, influenced by deflationary CPI (-0.3% in September 2025).
• Enoxaparin Sodium production costs experienced upward pressure in Q3 2025 due to heparin feedstock supply concerns.
• Demand for Enoxaparin Sodium was supported by robust industrial production, rising 6.5% year-on-year in September 2025.
• The pharmaceutical industry in China experienced rapid growth in 2025, guided by favorable policy support.
• China's Manufacturing Index contracted in September 2025, signaling a broader economic slowdown.
• Retail sales growth of 3.0% year-on-year in September 2025 supported consumer demand and healthcare funding.
• Falling factory-gate prices, with PPI declining 2.3% year-on-year in September 2025, limited manufacturer pricing power.
• Trade flows for heparin and its salts decreased in both exports and imports from China during July 2025.
• A stable unemployment rate of 5.2% in September 2025 supported consistent incomes and robust healthcare funding.
Why did the price of Enoxaparin Sodium change in September 2025 in APAC?
• Deflationary CPI (-0.3% in September 2025) pressured Enoxaparin Sodium prices downward.
• Falling factory-gate prices (PPI -2.3% in September 2025) limited manufacturer pricing power.
• Heparin feedstock supply concerns in Q3 2025 created upward pressure on production costs.
Europe
• In Germany, the Enoxaparin Sodium Price Index rose in Q3 2025, driven by surging API costs and robust pharmaceutical demand.
• Enoxaparin Sodium production costs increased due to surging API costs in July 2025 and elevated industrial electricity prices in Q3 2025.
• Despite a 1.7% year-over-year PPI decrease in September 2025, operational costs rose 2.4% year-over-year due to CPI.
• Demand for pharmaceutical products, including Enoxaparin Sodium, strengthened in Germany in Q3 2025, supported by an aging population.
• A low unemployment rate of 3.9% in September 2025 supported healthcare funding, positively impacting Enoxaparin Sodium demand.
• Pharmaceutical supply chains maintained tight inventories in Q3 2025, reflecting reliance on just-in-time systems.
• New EU carbon border tax, effective January 2025, introduced additional costs for Enoxaparin Sodium API imports.
• Germany's Manufacturing Index was contracting in September 2025, while Pharmaceutical Manufacturing Production Output increased in Q3 2025.
Why did the price of Enoxaparin Sodium change in September 2025 in Europe?
• Surging costs for active pharmaceutical ingredients in July 2025 increased Enoxaparin Sodium production expenses.
• Elevated industrial electricity and natural gas prices in Q3 2025 contributed to higher manufacturing costs.
• Strengthening demand for pharmaceutical products in Germany during Q3 2025 supported upward price pressure.
For the Quarter Ending December 2022
North America
Enoxaparin Sodium's domestic market in North America showed a stable trend during the 4th quarter of 2022. Enoxaparin Sodium imports were halted during the first week of October due to China's Golden Week holiday.
Given the substantial product inventories, domestic suppliers were able to meet the demand for the majority of the quarter, and up until this point, offtakes in the end-user industries continued to be normal. The unanticipated increase in Covid cases in China caused a pattern shift in the market for Enoxaparin Sodium at the conclusion of the quarter. The broken supply chain did, however, gradually heal as the economy expanded, and there was a major decrease in port backlog in December.
Asia Pacific
In Q4 of 2022, Price trends for Enoxaparin Sodium in the Asia Pacific region during the fourth quarter of 2022 were stable. From October to December, FOB Shenzhen prices slightly decreased in China, going from $24955000 per MT to $24985000 per MT. Due to the closure of manufacturing facilities for the Golden Week, the first week of October saw a steady fall in Enoxaparin Sodium orders for China's API market. It was challenging for the market to catch up to the slight growth seen in some downstream businesses because Chinese traders had to deal with various conflicting signals after a one-week break, but strong demand kept the market afloat. Chinese suppliers and producers were able to meet the entire quarter's demand thanks to ample supplies there. The administration amended its zero-Covid rules in response to criticism and significant unrest in the nation in December, leaving it vulnerable again.
Europe
The market for Enoxaparin Sodium in the European region matched the trend in North America and showed steady market sentiments. Due to the unexpected rise in COVID cases, which resulted in a continuous fall in demand, international demand was higher in the first part of the quarter than it was in December. Nevertheless, the circumstances in Russia and Ukraine, as well as COVID-19 cases, all continued to have a negative effect on the overall market.
For The Quarter Ending September 2022
North America
The Third Quarter of 2022 saw a decline in the market trend in North America, which was supported by a decrease in downstream demand from the pharmaceutical and biopharmaceutical industries. Additionally, there was a severe shortage of Enoxaparin sodium on the market due to the significant drop in pricing and the need for Upstream feed Heparin sodium, which had a negative impact on the price of Enoxaparin sodium. Additionally, reduced freight costs as a result of affected trade operations during volatile fuel prices have a significant negative impact on the market price value of Enoxaparin sodium API. Additionally, pricing remained unchanged despite a modest rise in customer demand for enoxaparin sodium in the middle of the third quarter.
Asia Pacific
The Asia Pacific region witnessed a stagnant pricing trend for Enoxaparin Sodium in the third quarter of 2022. With ongoing adverse weather conditions in the APAC region throughout Q3 2022, the production units were halted, and zero covid policy implications affected the Enoxaparin sodium values. Also, with the rising inflammation and lowering consumer demand diminishing inquiries, the domestic merchants were forced to keep the quotations low. Furthermore, enough existing inventories among the domestic suppliers and traders kept the market for Enoxaparin sodium feeble. Towards the termination of Q3 2022, Prices for Enoxaparin Sodium FOB Shenzhen were fixed at USD 24900000 per MT in the domestic Chinese market with an average quarterly declination of 0.07%.
Europe
The third quarter of 2022 saw a decline in the price of enoxaparin sodium on the European market, supported by reduced exporting operations seen in the middle of a recurrence of Covid-19 cases in China, the critical exporter to numerous other locations. In addition, the value of the Enoxaparin sodium price was impacted by the decreased upstream feed Heparin sodium pricing and its necessity. Additionally, the market prices for Enoxaparin sodium were severely hampered by the drastic fall in downstream demand. Further, the geopolitical conflict between Russia and Ukraine has reduced trading activity, which has delayed shipments, decreased freight costs, and decreased API prices in the markets.
For the Quarter Ending June 2022
North America
The market trend in North America decreased in the Second Quarter of 2022, backed by its reduced downstream demand from the pharmaceutical and biopharmaceutical enterprises. Furthermore, the substantial reduction in the prices and demand for Upstream feed Heparin sodium jammed the availability of Enoxaparin sodium in the market, which badly affected Enoxaparin sodium prices. Additionally, affected trading activities amid fluctuated fuel prices result in lowered freight charges, severely affecting Enoxaparin sodium API's price value in the market. Further, the prices went stable with slight increment in Enoxaparin Sodium Requirement from customer side followed by the mid of second quarter.
Asia Pacific
The Asia Pacific region witnessed a stagnant pricing trend for Enoxaparin Sodium in the second quarter of 2022. As the number of Covid-19 cases in China increased near the end of Q1, exporting activities remained hampered, which somewhere impacted the prices for Enoxaparin Sodium. The market value of Enoxaparin sodium was affected by the decreased upstream feed Heparin sodium prices. Also, the values of Enoxaparin Sodium were undermined by reduced export-import activity from China, the top exporter to other regions, which resulted in stockpiled shipments, and slower manufacturing activities. Demand for the product remained consistent over the course of the quarter. Prices for Enoxaparin Sodium FOB Shenzhen were fixed at $24950000 per MT in the domestic Chinese market, and prices for Ex-Ahmedabad in India were agreed upon at $22162208 per MT in the month of June.
Europe
European Market witnessed a downward trend in the prices of Enoxaparin sodium throughout the second quarter of 2022, backed by lowered exporting activities observed amidst the resurgence of Covid-19 cases in China being the major exporter to various other regions. Besides that, the reduced upstream feed Heparin sodium prices and its requirement impacted the Enoxaparin sodium price value. Also, the massive decline in downstream demand heavily impeded the prices of Enoxaparin sodium in the market. Additionally, decrease in trading activities amid the Russian-Ukraine geopolitical tension, leading to the delayed shipment, a decline in freight charges, and a reduction in API prices in the markets.
